<DOC>
	<DOCNO>NCT00002150</DOCNO>
	<brief_summary>To characterize safety efficacy fix dose MDL 28,574A administer alone combination zidovudine ( AZT ) patient asymptomatic mildly symptomatic HIV infection . To examine demographic effect population pharmacokinetics pharmacodynamics MDL 28,574A alone combination AZT .</brief_summary>
	<brief_title>A Study Safety Efficacy Chronically Administered MDL 28,574A Treatment HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection . Asymptomatic mildly symptomatic . CD4 count 100 300 cells/mm3 . Prior Medication : Allowed : Prior antiretroviral agent 6 month per agent . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Unable unwilling comply study procedure . Concurrent Medication : Excluded : Chemoprophylactic therapy mycobacterial infection . Any nonstudy prescription medication without approval investigator . Patients follow prior condition exclude : History grade 3 4 toxicity &lt; = 600 mg/day AZT . History intolerance lactose . Chronic diarrhea within 6 month prior study entry . Unexplained intermittent chronic fever , defined temperature &gt; = 38.5 C 7 day within 30 day prior study entry . Prior Medication : Excluded : Antiretroviral therapy within 2 week prior study entry . Prior HIV vaccine . Biological response modifier within 30 day prior study entry . Prior foscarnet . Any investigational drug washout &lt; 5 halflives prior study entry . Any medication know alter renal , hepatic , hematologic / immunologic function ( barbiturate , phenothiazine , cimetidine , immunomodulators , etc . ) within 14 day prior study entry . Recent history alcohol and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>MDL 28574</keyword>
</DOC>